The overall purpose of the Animal Models Core (Core D) is to facilitate the accomplishment of the translational research goals and objectives of the SPORE by providing investigators with assistance in the design and generation of transgenic and knockout/knockin mouse strains, a centralized repository for these mouse strains, and material of common interest, such as dissected tissues, DNA, RNA, or protein extracts from these mouse strains.
The specific aims of the Animal Models Core are to: 1. Generate and provide transgenic and knockout/knockin mouse strains as needed by SPORE investigators. 2. Serve as a centralized repository and breeding service for mouse strains used by SPORE investigators. 3. Provide SPORE laboratories with dissected tissues, DNA, RNA, and proteins from the mouse mutants utilized by the investigators. With the recent establishment of a standardized preclinical trial protocol developed by our Core and based on phase II and III patient clinical trials, we anticipate further increased use of our Core by members of our SPORE.

Public Health Relevance

The Animal Models Core is an essential component of our SPORE in Prostate Cancer because it facilitates the timely conduct of research by centralizing services designed to prioritize the needs of our SPORE investigators: maintaining colonies of mice ready for use in preclinical studies and procuring and banking tissue from these mice for characterization of molecular markers and for RNA, DNA, and protein studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092629-12
Application #
8555203
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2001-09-14
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
12
Fiscal Year
2012
Total Cost
$207,727
Indirect Cost
$94,153
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Han, SoHyun; Stoyanova, Radka; Lee, Hansol et al. (2018) Automation of pattern recognition analysis of dynamic contrast-enhanced MRI data to characterize intratumoral vascular heterogeneity. Magn Reson Med 79:1736-1744
Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245
Kinsella, Netty; Helleman, Jozien; Bruinsma, Sophie et al. (2018) Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 7:83-97
Hieronymus, Haley; Murali, Rajmohan; Tin, Amy et al. (2018) Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7:
Scher, Howard I; Graf, Ryon P; Schreiber, Nicole A et al. (2018) Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncol 4:1179-1186
Bielski, Craig M; Zehir, Ahmet; Penson, Alexander V et al. (2018) Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet 50:1189-1195
Luo, Jun; Attard, Gerhardt; Balk, Steven P et al. (2018) Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol 73:715-723
Settleman, Jeffrey; Sawyers, Charles L; Hunter, Tony (2018) Challenges in validating candidate therapeutic targets in cancer. Elife 7:
Miyazawa, Miki; Subbaramaiah, Kotha; Bhardwaj, Priya et al. (2018) Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. Cancer Prev Res (Phila) 11:215-226
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467

Showing the most recent 10 out of 505 publications